Highlights NanoVibronix, Inc.

Equities

NAOV

US63008J6038

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-01 pm EDT			5-day change	1st Jan Change
0.69 ^USD	-6.12%		-8.00%	-40.00%

Apr. 08	NanoVibronix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	NanoVibronix, Inc. Enters into Letter of Intent with APOGEPHA Arzneimittel GmbH to Explore European Distribution Opportunity	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

NanoVibronix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 08	CI
NanoVibronix, Inc. Enters into Letter of Intent with APOGEPHA Arzneimittel GmbH to Explore European Distribution Opportunity	Dec. 04	CI
NanoVibronix, Inc. Signs Research Agreement for Clinical Study of UroShield with University of Michigan	Nov. 28	CI
NanoVibronix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
NanoVibronix, Inc. Gains Approval for Inclusion of UroShield Products in NHS Prescription Services' Drug Tariff	23-09-27	CI
NanoVibronix Says It's Working to Understand Implications of CMS Decision Related to PainShield Device	23-08-29	MT
NanoVibronix, Inc. Applies for Inclusion of Uroshield Products in Nhs Prescription Services' Drug Tariff	23-08-28	CI
NanoVibronix Extends Distribution Agreement with Its Largest Distributor for PainShield and PainShield Plus	23-08-23	CI
NanoVibronix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
NanoVibronix Announces Distribution Agreement with Mio-Guard	23-06-14	CI
NanoVibronix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
NanoVibronix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-17	CI
NanoVibronix, Inc. Receives Positive Final Results of Independent Lifecycle Testing of PainShield Prompted by Centers for Medicare and Medicaid Services	23-03-28	CI
NanoVibronix Files Provisional Patent Application in US for UroShield Ultra; Shares Jump	23-03-21	MT
NanoVibronix, Inc. Files Provisional U.S. Patent Application for UroShield Ultra	23-03-21	CI
Nanovibronix, Inc. Announces Positive Results from Independent Product Trial of UroShield for Patients with A Spinal Cord Injury	23-03-14	CI
NanoVibronix Regains Nasdaq Compliance for Listing	23-03-03	MT
NanoVibronix, Inc. Announces Partnership with Peak Medical, Ltd	22-12-13	CI
NanoVibronix Says It Received FDA Premarket Clearance for Pain Therapy Device; Shares Surge	22-11-28	MT
NanoVibronix Receives FDA 510(k) Premarket Clearance for PainShield Plus	22-11-28	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights NanoVibronix, Inc.

Equities

NAOV

US63008J6038

Highlights

Filters